Paul Campanelli named president and CEO of Endo International

23 September 2016

Ireland-incorprated drugmaker Endo International (Nasdaq: ENDP) has named Paul Campanelli as president and chief executive, effective immediately.

Mr Campanelli currently serves as president of Endo's Generic and OTC drugs business, Par Pharmaceutical, which accounts for around 60% of Endo's total revenues through the first half of 2016. Mr Campanelli, who will also join Endo's board of directors, succeeds Rajiv De Silva , who has stepped down as president, CEO and a member of the board.

Mr Campanelli, aged 54, joined Endo in 2015 following Endo's acquisition of Par Pharmaceutical, where he had served as CEO since 2012. While CEO of Par, he built a strong leadership team and an industry-leading generics business. Specifically, during his tenure, Par significantly increased total revenue, acquired JHP Pharmaceuticals and established a presence in the European generics market. Since joining Endo, Mr Campanelli has overseen the company's US Generic Pharmaceuticals business.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK